Observational studyChest2025
Pregnancy Outcomes in 53 Female Lung Transplant Recipients.
Observational study in Chest, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLimited data exist to inform and appropriately counsel female lung transplant (LuT) recipients regarding pregnancy after transplantation. STUDY QUESTION: What are the modifiable factors that impact pregnancy outcomes in female LuT recipients? STUDY DESIGN AND
methodsRetrospective observational analysis was performed on female LuT recipients who reported pregnancies after transplantation to the Transplant Pregnancy Registry International (TPRI).
resultsFifty-three recipients who underwent LuT from 1991 through 2021 reported 72 pregnancies to TPRI. Predominant indications for transplant were cystic fibrosis (60%) and pulmonary hypertension (19%). Contraceptive use after transplantation was 36%. Most recipients (54%) reported unplanned pregnancies. The live birth rate was 62%, resulting in 46 live births. Approximately 60% of births were premature (< 37 weeks' gestational age [GA]) and of low birth weight (LBW) (< 2,500 g). Birth defects were seen in 7 children (16%), none with mycophenolic acid (MPA) embryopathy. Three neonatal deaths resulted from extreme prematurity; 43 remaining children are healthy. Twenty recipients (38%) have died a median of 23.6 years after LuT. Recipients with transplant-to-conception interval of ≤ 2 years had no difference in mortality compared with those with transplant-to-conception interval of > 2 years (hazard ratio [HR], 1.26; 95% CI, 0.50-3.12; P = .625). Recipients whose first pregnancy after transplantation was unplanned showed lower survival (HR, 7.02; 95% CI, 1.35-36.45; P = .020). Newborns of LuT recipients with planned vs unplanned pregnancies had higher median GA (36.9 weeks vs 34 weeks; P = .025) and birth weight (2,639 g vs 2,155 g; P = .047), and significantly lower risk of LBW for singletons (OR, 0.26; 95% CI, 0.07-0.94; P = .036).
interpretationSuccessful pregnancy after LuT is achievable, however, not without risks for mother and offspring. Our results showed that planned pregnancies resulted in higher GA and birth weight live births and showed lower mortality after pregnancy. TPRI data show 54% of recipients reported unplanned pregnancies, an obvious area for improvement. Planning pregnancy is the most modifiable factor for mitigating risks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.